AIZ-AR Stable 22Rv1 Luciferase Reporter Cell Line

Unit

1×10⁶ cells / 1.0 ml

Cell Type

Stable (KO/Expressing) Cells

Tissue Type

Prostate

Organism

Human (H. sapiens)

Donor History

Male

,

Prostate carcinoma

Growth Properties

Adherent

,

epithelial-like

Growth Conditions

PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. Dulbecco's Modified Eagle Medium (DMEM)

,

High Glucose (TM500) + 10% FBS + 4 mM L-Glutamine (G275) + 1 mM Sodium Pyruvate (TM057) + 1% Penicillin/Streptomycin Solution (G255)

,

37.0°C

,

5% CO₂. 0.2 mg/ml Hygromycin (G265) for selection. Note: Selection drugs should be added to the culture medium after the first passage to ensure cells have recovered from freeze-thaw conditions.

Immortalization Method
Full Information

https://www.abmgood.com/aiz-ar-stable-22rv1-luciferase-reporter-cell-line.html

Katalogové číslo: T3104 Kategorie: ,
Popis

The androgen receptor (AR) is a ligand-activated transcription factor involved in developmental and psychological processes and implicated in the pathogenesis of prostatic hyperplasia, prostate cancer, and altered pubertal development. The AIZ-AR Stable 22Rv1 Luciferase Reporter Cell Line (Clone 8) contains a reporter plasmid with three copies of the androgen response region with a downstream androgen response element which allows for the detection of AR ligands through the induction of luciferase activity as early as 8 hours after treatment. The reporter plasmid p3ARR/ARE-luc2P/minP/hygro was successfully transfected into the 22Rv1 cells using the Fugene HD transfection reagent. These immortalized cells are functional for over 25 passages after cryopreservation making them a reproducible and sensitive tool for the detection of AR ligands during research investigating novel pharmaceutical drugs or screening for environmental pollutants that may disrupt endocrine function through AR interaction.

O značce
Applied Biological Materials (abm) je jedním z našich klíčových dodavatelů pro biotechnologický průmysl. Společnost byla založena v roce 2004 a již více než deset let podporuje vědecké objevy v oblasti přírodních věd a vývoje léčiv. Její sídlo se nachází ve Vancouveru v Kanadě. ABM je pro nás neocenitelným partnerem zejména v  oblasti dodávek buněčných kultur, genových a virových vektorů, produktů pro molekulární biologii a PCR, nástrojů pro technologie CRISPR a RNAi, protilátek i základních reagencií pro molekulárně genetické procesy.